{
  "@context": "aku-v2",
  "@type": "concept",
  "@id": "wsmg:health-sciences:medicine:surgery:vascular:pharmacology:pharm-003",
  "metadata": {
    "version": "2.1.0",
    "created": "2026-01-08T20:30:00.000Z",
    "modified": "2026-01-08T20:30:00.000Z",
    "contributors": ["copilot-agent", "vascular-surgery-sme"],
    "confidence": 0.93,
    "status": "pending-quality-check",
    "language": "en",
    "licenses": ["CC-BY-4.0"]
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology",
    "subdomain": "anticoagulation",
    "type": "definition",
    "difficulty": "intermediate",
    "importance": "critical",
    "isNativeDomain": true,
    "board_yield": "HIGH"
  },
  "content": {
    "title": "Direct Thrombin Inhibitors",
    "summary": "Direct thrombin inhibitors (DTIs) are anticoagulants that directly bind to and inhibit thrombin without requiring antithrombin as a cofactor. They are particularly valuable in heparin-induced thrombocytopenia and have predictable pharmacokinetics.",
    "definition": "A class of anticoagulants that directly bind and inhibit thrombin (factor IIa), independent of antithrombin cofactor activity, blocking both fibrin-bound and free thrombin",
    "mechanism_of_action": {
      "thrombin_inhibition": {
        "direct_binding": "Binds directly to active site and/or exosite of thrombin",
        "no_cofactor": "Does not require antithrombin III (unlike heparin)",
        "inhibits_both": "Blocks both free circulating thrombin AND fibrin-bound thrombin"
      },
      "advantage_over_heparin": [
        "Can inhibit clot-bound thrombin (heparin cannot)",
        "Not inhibited by platelet factor 4",
        "Predictable dose-response",
        "Does not cause HIT"
      ]
    },
    "classification": {
      "by_binding": {
        "bivalent": {
          "definition": "Binds both active site and exosite 1 of thrombin",
          "examples": "Hirudin, bivalirudin, lepirudin",
          "binding": "Essentially irreversible"
        },
        "univalent": {
          "definition": "Binds only to active site",
          "examples": "Argatroban, dabigatran, melagatran",
          "binding": "Reversible"
        }
      }
    },
    "specific_agents": {
      "argatroban": {
        "route": "IV continuous infusion",
        "half_life": "40-50 minutes",
        "metabolism": "Hepatic (cytochrome P450)",
        "dose_adjustment": "Reduce in hepatic impairment",
        "renal_effect": "No dose adjustment for renal failure",
        "monitoring": "aPTT (target 1.5-3x baseline)",
        "indications": [
          "HIT with or without thrombosis",
          "PCI in patients with HIT"
        ],
        "reversal": "No specific antidote; short half-life allows effect to wear off"
      },
      "bivalirudin": {
        "route": "IV bolus and infusion",
        "half_life": "25 minutes (normal renal function)",
        "metabolism": "Proteolytic cleavage and renal",
        "dose_adjustment": "Reduce in renal impairment",
        "monitoring": "ACT for PCI, aPTT for medical",
        "indications": [
          "PCI (alternative to heparin)",
          "HIT requiring PCI"
        ],
        "advantages": [
          "Short half-life",
          "Lower bleeding risk than heparin+GP IIb/IIIa in some settings"
        ],
        "reversal": "No antidote; short half-life"
      },
      "dabigatran": {
        "route": "Oral",
        "half_life": "12-17 hours",
        "metabolism": "Primarily renal (80%)",
        "dose_adjustment": "Reduce or avoid in severe renal impairment",
        "monitoring": "Not routinely monitored; thrombin time if needed",
        "indications": [
          "Atrial fibrillation stroke prevention",
          "VTE treatment and prevention"
        ],
        "reversal": {
          "specific": "Idarucizumab (Praxbind) - monoclonal antibody fragment",
          "other": "Hemodialysis can remove drug"
        }
      },
      "desirudin_lepirudin": {
        "note": "Hirudin derivatives; lepirudin withdrawn from market",
        "limitations": [
          "Recombinant hirudin origin",
          "Can cause antibody formation",
          "Renal clearance (problematic in HIT with renal failure)"
        ]
      }
    },
    "clinical_applications": {
      "HIT": {
        "role": "First-line alternative anticoagulation",
        "agents": [
          "Argatroban (hepatic clearance - good for renal failure)",
          "Bivalirudin (shorter half-life)"
        ],
        "critical": "Must stop all heparin products and switch immediately"
      },
      "PCI": {
        "bivalirudin": "Alternative to heparin, especially in bleeding risk",
        "argatroban": "Option for HIT patients requiring PCI"
      },
      "VTE_prevention_treatment": {
        "dabigatran": "FDA-approved for DVT/PE and stroke prevention in AF"
      }
    },
    "laboratory_monitoring": {
      "aPTT": {
        "use": "Argatroban, bivalirudin at sub-PCI doses",
        "target": "1.5-3x baseline (argatroban)"
      },
      "ACT": {
        "use": "Bivalirudin for PCI",
        "target": "Per institutional protocol"
      },
      "ECT_TT": {
        "use": "Dabigatran level assessment if needed",
        "interpretation": "Thrombin time very sensitive to dabigatran"
      },
      "INR_effect": "Argatroban falsely elevates INR - complicates warfarin transition"
    },
    "reversal_and_bleeding": {
      "argatroban": {
        "reversal": "Stop infusion; half-life ~45 min",
        "bleeding": "Supportive care, transfusion"
      },
      "bivalirudin": {
        "reversal": "Stop infusion; half-life ~25 min",
        "hemodialysis": "Can remove some drug"
      },
      "dabigatran": {
        "specific_reversal": "Idarucizumab (5g IV)",
        "hemodialysis": "Removes ~60% over 4 hours",
        "supportive": "PCC, activated charcoal if recent ingestion"
      }
    },
    "comparison_to_other_anticoagulants": {
      "vs_heparin": [
        "More predictable response",
        "No HIT risk",
        "Can inhibit clot-bound thrombin",
        "More expensive"
      ],
      "vs_factor_Xa_inhibitors": [
        "DTIs inhibit thrombin directly",
        "Factor Xa inhibitors block upstream in cascade",
        "Dabigatran has specific reversal agent"
      ]
    }
  },
  "skos": {
    "prefLabel": {"@language": "en", "@value": "Direct Thrombin Inhibitors"},
    "altLabel": [
      {"@language": "en", "@value": "DTI"},
      {"@language": "en", "@value": "Direct thrombin inhibitor anticoagulants"},
      {"@language": "en", "@value": "Factor IIa inhibitors"}
    ],
    "definition": {"@language": "en", "@value": "Anticoagulants that directly bind and inhibit thrombin independent of antithrombin"},
    "notation": "pharm-003"
  },
  "relationships": {
    "skos:broader": [{"@id": "wsmg:health-sciences/medicine/surgery/vascular/pharmacology", "skos:prefLabel": "Vascular Pharmacology"}],
    "skos:related": [
      {"@id": "wsmg:health-sciences:medicine:surgery:vascular:pharmacology:pharm-001", "skos:prefLabel": "Heparin Pharmacology"},
      {"@id": "wsmg:health-sciences/medicine/surgery/vascular/pathology/hit", "skos:prefLabel": "Heparin-Induced Thrombocytopenia"}
    ],
    "enables": [
      {"@id": "wsmg:health-sciences/medicine/surgery/vascular/pathology/hit-management", "reason": "Alternative anticoagulation in HIT"}
    ]
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codingSystem": "ATC",
      "codeValue": "B01AE",
      "description": "Direct thrombin inhibitors"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "MeSH",
      "codeValue": "D015951",
      "uri": "http://id.nlm.nih.gov/mesh/D015951",
      "description": "Factor IIa Inhibitors"
    }
  ],
  "pedagogical": {
    "learning_objectives": [
      "Explain the mechanism of action of direct thrombin inhibitors",
      "Compare bivalent and univalent DTI binding",
      "List specific DTIs and their pharmacokinetic properties",
      "Select appropriate DTI for HIT and PCI settings",
      "Describe reversal strategies for DTI anticoagulation"
    ],
    "clinical_pearls": [
      "DTIs can inhibit clot-bound thrombin (heparin cannot)",
      "Argatroban: hepatic metabolism - good for HIT with renal failure",
      "Argatroban falsely elevates INR - complicates warfarin transition",
      "Dabigatran has specific reversal: idarucizumab (Praxbind)",
      "Bivalirudin has very short half-life (~25 min) - good for procedures"
    ],
    "estimated_time": "25min",
    "target_audience": ["vascular_surgery_residents", "pharmacy", "hematology", "cardiology"]
  }
}
